This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ross River Virus vaccine

Nanotherapeutics, Inc.

Drug Names(s): Ross River Virus (RRV) vaccine

Description: Baxter is developing a formalin treated, UV inactivated, vero cell-derived vaccine for the Ross River Virus, an arthropod-borne virus that causes the non-fatal Ross River Fever. While this fever does not always cause symptoms, flu-like symptoms such as fever, chills, headaches, rash, and pains in the muscles and joints may occur.

Deal Structure: Nanotherapeutics and Baxter
In December 2014, Baxter International announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics. Financial details were not disclosed.

Ross River Virus vaccine News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug